Arcutis Biotherapeutics, Inc. (ARQT) Q3 2025 10-Q Quarterly Report
Arcutis Biotherapeutics, Inc. (ARQT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 28, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Arcutis Biotherapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New regulatory risk from One Big Beautiful Bill Act (Jul 2025) cutting Medicaid spending by $1 trillion, potentially lowering life sciences revenue
- • Most material update: tax law changes including possible increased U.S. tax expense and one-time charges affecting deferred tax asset values
Arcutis Biotherapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$99M
▲ +121.7% YoY▲ +21.7% QoQ
Net Income
$7M
▲ +117.8% YoY▲ +146.6% QoQ
Operating Margin
8.6%
▲ +9588bp YoY▲ +2652bp QoQ
Net Margin
7.5%
▲ +10028bp YoY▲ +2696bp QoQ
ROE
4.7%
Total Assets
$371M
EPS (Diluted)
$0.06
▲ +118.2% YoY▲ +150.0% QoQ
Operating Cash Flow
-$2M
▲ +94.9% YoY▼ -641.4% QoQ
Source: XBRL data from Arcutis Biotherapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Arcutis Biotherapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.